GSK plc (GLAXF) Financials
GLAXF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2026 | 95.6 billion | 71.1 billion |
| June 30, 2026 | 81.2 billion | 58.6 billion |
| March 31, 2026 | 83.0 billion | 60.0 billion |
| Dec. 31, 2025 | 82.1 billion | 60.6 billion |
GLAXF Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2026 | 3.1 billion | ? |
| June 30, 2026 | 2.9 billion | ? |
| March 31, 2026 | 921.4 million | ? |
| Dec. 31, 2025 | 2.0 billion | ? |
GLAXF Net Income
| Date | Net Income |
|---|---|
| Sept. 30, 2026 | 2.0 billion |
| June 30, 2026 | 572.1 million |
| March 31, 2026 | 2.4 billion |
| Dec. 31, 2025 | 854.5 million |
GLAXF Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2026 | 3.9 billion | 28.9 billion | - |
| June 30, 2026 | 4.1 billion | 18.3 billion | - |
| March 31, 2026 | 4.5 billion | 18.5 billion | - |
| Dec. 31, 2025 | 4.6 billion | 19.8 billion | 1.1 billion |
GLAXF Shares Outstanding
GLAXF Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2026 | 485.6 million | 2.4 billion | 3.2 billion | - |
| June 30, 2026 | 431.4 million | 2.3 billion | 2.9 billion | - |
| March 31, 2026 | 584.8 million | 2.2 billion | 2.8 billion | - |
| Dec. 31, 2025 | 769.9 million | 3.1 billion | 3.6 billion | - |
GLAXF Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2026 | 11.5 billion | 2.9 billion |
| June 30, 2026 | 11.1 billion | 2.7 billion |
| March 31, 2026 | 10.1 billion | 2.5 billion |
| Dec. 31, 2025 | 11.6 billion | 3.5 billion |
GLAXF
Price: $23.40
Dividend Yield: 3.18%
Payout Ratio: 51.48%
Earnings Per Share: 1.42 USD
P/E Ratio: 16.04
Exchange: PNK
Sector: Healthcare
Industry: Drug Manufacturers - General
Country: United Kingdom
Market Capitalization: 91.2 billion
Average Dividend Frequency: 8
Years Paying Dividends: 23
DGR3: 19.79%
DGR5: 8.56%
DGR10: 2.50%
DGR20: 7.16%